RegCell Co., Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
RegCell Co., Ltd. - overview
Established
2016
Location
Suita-shi, Osaka, Japan
Primary Industry
Biotechnology
About
Based in Japan, RegCell Co. , Ltd. focuses on innovative immune system control technologies, specifically the development and application of regulatory T cells (Tregs) for therapeutic solutions in various medical conditions. RegCell Co.
, Ltd. , founded in 2016, specializes in immune system control technologies. The company is headquartered in Suita-shi, Japan, and has completed a total of 4 funding deals. The most recent funding occurred on March 18, 2025, when RegCell secured USD 8.
5 mn in a Grant round, led by the Japan Agency for Medical Research and Development. Overall, the company has raised USD 8. 5 mn to date. RegCell Co.
, Ltd. specializes in innovative immune system control technologies through the development and application of regulatory T cells (Tregs). Their offerings focus on advanced therapeutic solutions aimed at modulating immune responses in conditions such as autoimmune diseases, cancer, and transplant rejection. The company targets healthcare providers, research institutions, and pharmaceutical companies across Japan, the United States, and Europe, aiming to improve patient outcomes in immunological scenarios.
RegCell Co. , Ltd. generates revenue through direct sales and partnerships with healthcare organizations and research institutions that utilize their Treg-based therapies. Revenue is derived from agreements with hospitals and clinics, where RegCell's products are integrated into treatment regimens or clinical trials.
The company may also engage in collaborations with pharmaceutical firms for the co-development of specialized therapies, aligning with premium pricing strategies typically seen in the biopharmaceutical sector. In March 2025, RegCell Co. , Ltd. raised USD 8.
5 mn in a funding round, part of a larger USD 45. 8 mn seed and grant financing. The company plans to utilize this funding to build its epigenetic reprogramming platform through clinical proof-of-concept. RegCell is focused on expanding its product line and enhancing its presence in new markets, including potential expansion into North America and Europe by 2026.
Current Investors
Nissay Capital, Fujifilm Holdings Corporation, MIRAIDOOR
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Specialty Pharmaceuticals
Website
www.regcell.jp
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.